Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01524562 · ClinicalTrials.gov registry record
HIV Accelerated Liver Disease in Uganda
A clinical trial, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- 786
- Enrollment target
NCT01524562 is a clinical trial that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 786 participants.
The verdict
NCT01524562 has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- 786 participants
- Enrollment target
Study Summary
Background: \- Liver disease is a leading cause of death in people who have the human immunodeficiency virus (HIV). It especially affects those who have both HIV and hepatitis B or C viruses. Most research on HIV-related liver disease has been conducted in North America and Europe. However, HIV-related liver disease in Uganda and other African nations may involve other diseases that are not common in the West, and may not involve hepatitis B or C. Researchers want to study HIV-related liver disease in Uganda to learn more about the differences between Western and African trends of this disease. Objectives: \- To study HIV-related liver disease in rural Uganda. Eligibility: * Individuals at least 18 years of age who were tested for possible liver disease. Some participants will have HIV infection; others will be uninfected. * All participants will be from rural areas of Uganda. Design: * Participants will have at least two study visits. * Participants will have a physical exam and medical history. They will complete a questionnaire about health and quality of life. Blood, urine, and stool samples will be collected. Participants will also have a liver scan to check for liver scarring, and an ultrasound to take images of the liver. * Participants who may have liver disease will visit a local hospital for more tests. A liver biopsy will be performed to collect liver tissue samples.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 786 participants |
| Start Date | 2011-12-20 |
| Est. Completion | 2019-12-17 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01524562
The ClinicalTrials.gov registry entry for NCT01524562 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 786 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01524562 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01524562 about?
NCT01524562 is a clinical study titled "HIV Accelerated Liver Disease in Uganda". Background: \- Liver disease is a leading cause of death in people who have the human immunodeficiency virus (HIV). It especially affects those who have both HIV and hepatitis B or C viruses. Most research on HIV-related liver disease has been conducted in North America and Europe. However, HIV-rel...
What is the current status of trial NCT01524562?
This trial is currently completed. The enrollment target is 786 participants. The study started on 2011-12-20. Estimated completion is 2019-12-17.
Who is sponsoring clinical trial NCT01524562?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.